×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
09:02 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
1/13
08:55 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
1/12
08:55 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
1/12
08:36 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
12/17
08:31 am
mbrx
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
High
Report
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
12/15
02:08 pm
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.
12/11
07:20 am
mbrx
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/10
08:30 am
mbrx
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
High
Report
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
1/13
08:55 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Jan 13
Low
Report
Form 8-K Moleculin Biotech, Inc. For: Jan 13
1/12
08:36 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Jan 12
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Jan 12
1/7
08:30 am
mbrx
Form 8-K Moleculin Biotech, Inc. For: Jan 07
Medium
Report
Form 8-K Moleculin Biotech, Inc. For: Jan 07
1/7
06:02 am
mbrx
Form EFFECT Moleculin Biotech, Inc.
Low
Report
Form EFFECT Moleculin Biotech, Inc.
1/2
04:01 pm
mbrx
Form DEF 14A Moleculin Biotech, Inc. For: Feb 05
Medium
Report
Form DEF 14A Moleculin Biotech, Inc. For: Feb 05
12/23
04:48 pm
mbrx
Form S-3 Moleculin Biotech, Inc.
Medium
Report
Form S-3 Moleculin Biotech, Inc.
12/23
04:23 pm
mbrx
Form 424B5 Moleculin Biotech, Inc.
Low
Report
Form 424B5 Moleculin Biotech, Inc.
12/22
05:28 pm
mbrx
Form PRER14A Moleculin Biotech, Inc.
Medium
Report
Form PRER14A Moleculin Biotech, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
TOP News Decliners
3/19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]
-50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: